Cargando…

Immunogenicity of a bivalent killed thimerosal-free oral cholera vaccine, Euvichol, in an animal model

PURPOSE: An oral cholera vaccine (OCV), Euvichol, with thimerosal (TM) as preservative, was prequalified by the World Health Organization (WHO) in 2015. In recent years, public health services and regulatory bodies recommended to eliminate TM in vaccines due to theoretical safety concerns. In this s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Eun Young, Lee, Sena, Rho, Semi, Kim, Jae-Ouk, Choi, Seuk Keun, Lee, Young Jin, Park, Joo Young, Song, Manki, Yang, Jae Seung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Vaccine Society 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082675/ https://www.ncbi.nlm.nih.gov/pubmed/30112349 http://dx.doi.org/10.7774/cevr.2018.7.2.104

Ejemplares similares

A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines()
por: Russo, Paola, et al.
Publicado: (2018)

Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines
por: Capeding, Maria Rosario Z., et al.
Publicado: (2017)

Natural killer T cell sensitization during neonatal respiratory syncytial virus infection induces eosinophilic lung disease in re-infected adult mice
por: Lee, Seung Young, et al.
Publicado: (2017)

A Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia
por: Desai, Sachin N., et al.
Publicado: (2015)

Safety and Immunogenicity Assessment of an Oral Cholera Vaccine through Phase I Clinical Trial in Korea
por: Baik, Young Ok, et al.
Publicado: (2014)

Immunogenicity of a Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine, Shanchol, in Haiti
por: Charles, Richelle C., et al.
Publicado: (2014)

Immunogenicity of a killed bivalent whole cell oral cholera vaccine in forcibly displaced Myanmar nationals in Cox's Bazar, Bangladesh
por: Chowdhury, Fahima, et al.
Publicado: (2020)

The Euvichol story – Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships
por: Odevall, Lina, et al.
Publicado: (2018)

Safety and immunogenicity of an inactivated thimerosal‐free influenza vaccine in infants and children
por: Nolan, Terry, et al.
Publicado: (2009)

Cross-Protective Shigella Whole-Cell Vaccine With a Truncated O-Polysaccharide Chain
por: Kim, Min Jung, et al.
Publicado: (2018)

Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein
por: Choi, Jung-ah, et al.
Publicado: (2020)

Euvichol-plus vaccine campaign coverage during the 2017/2018 cholera outbreak in Lusaka district, Zambia: a cross-sectional descriptive study
por: Mukonka, Victor M, et al.
Publicado: (2023)

Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India
por: Raghava Mohan, Venkata, et al.
Publicado: (2019)

Evaluation of Thimerosal Removal on Immunogenicity of Aluminum Salts Adjuvanted Recombinant Hepatitis B Vaccine
por: Mahboubi, Arash, et al.
Publicado: (2012)

Erratum: Addition of Author's Affiliated Institute and Correction of the Author's Name. Corrected: Safety and Immunogenicity Assessment of an Oral Cholera Vaccine through Phase I Clinical Trial in Korea
por: Baik, Yeong Ok, et al.
Publicado: (2014)

Effectiveness of two doses of Euvichol-plus oral cholera vaccine in response to the 2017/2018 outbreak: a matched case–control study in Lusaka, Zambia
por: Sialubanje, Cephas, et al.
Publicado: (2022)

Thimerosal and Animal Brains: New Data for Assessing Human Ethylmercury Risk
por: Barrett, Julia R.
Publicado: (2005)

Thimerosal: current sources of contact in Brazil()
por: Rocha, Vanessa Barreto, et al.
Publicado: (2014)

Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein
por: Goo, Junghyun, et al.
Publicado: (2020)

Molecular Insights Into the Evolutionary Pathway of Vibrio cholerae O1 Atypical El Tor Variants
por: Kim, Eun Jin, et al.
Publicado: (2014)

Effect of thimerosal on thyroid hormones metabolism in rats
por: Pantaleão, Thiago U, et al.
Publicado: (2017)

A Randomized, Placebo-Controlled Trial of the Bivalent Killed, Whole-Cell, Oral Cholera Vaccine in Adults and Children in a Cholera Endemic Area in Kolkata, India
por: Mahalanabis, Dilip, et al.
Publicado: (2008)

Comparative Effectiveness of COVID-19 Bivalent Versus Monovalent mRNA Vaccines in the Early Stage of Bivalent Vaccination in Korea: October 2022 to January 2023
por: Kim, Ryu Kyung, et al.
Publicado: (2023)

Development of Safe and Non-Self-Immunogenic Mucosal Adjuvant by Recombinant Fusion of Cholera Toxin A1 Subunit with Protein Transduction Domain
por: Shim, Byoung-Shik, et al.
Publicado: (2018)

Antigenic profile of heat-killed versus thimerosal-treated Leishmania major using sodium dodecyl sulfate-polyacrylamide gel electrophoresis
por: Arjmand, Reza, et al.
Publicado: (2015)

Vibriocidal Antibody Responses to a Bivalent Killed Whole-Cell Oral Cholera Vaccine in a Phase III Trial in Kolkata, India
por: Kanungo, Suman, et al.
Publicado: (2014)

Immunogenicity of Bivalent Human Papillomavirus DNA Vaccine Using Human Endogenous Retrovirus Envelope-Coated Baculoviral Vectors in Mice and Pigs
por: Lee, Hee-Jung, et al.
Publicado: (2012)

An Open Label Non-inferiority Trial Assessing Vibriocidal Response of a Killed Bivalent Oral Cholera Vaccine Regimen following a Five Year Interval in Kolkata, India
por: Kanungo, Suman, et al.
Publicado: (2015)

Efficacy of a bivalent killed whole-cell cholera vaccine over five years: a re-analysis of a cluster-randomized trial
por: Fong, Youyi, et al.
Publicado: (2018)

Safety, Tolerability, and Immunogenicity of COVID-19 Bivalent Vaccination
por: Saxena, Divyasha, et al.
Publicado: (2023)

Thimerosal Exposure and the Role of Sulfation Chemistry and Thiol Availability in Autism
por: Kern, Janet K., et al.
Publicado: (2013)

Thimerosal-Preserved Hepatitis B Vaccine and Hyperkinetic Syndrome of Childhood
por: Geier, David A., et al.
Publicado: (2016)

Effect of thimerosal, methylmercury, and mercuric chloride in Jurkat T Cell Line
por: Guzzi, Gianpaolo, et al.
Publicado: (2012)

An Age-stratified, Randomized Immunogenicity Trial of Killed Oral Cholera Vaccine with Delayed Second Dose in Cameroon
por: Ateudjieu, Jérôme, et al.
Publicado: (2022)

Safety of a bivalent, killed, whole-cell oral cholera vaccine in pregnant women in Bangladesh: evidence from a randomized placebo-controlled trial
por: Khan, Ashraful Islam, et al.
Publicado: (2019)

Long-term effectiveness of one and two doses of a killed, bivalent, whole-cell oral cholera vaccine in Haiti: an extended case-control study
por: Franke, Molly F, et al.
Publicado: (2018)

Newcastle disease virus vectored vaccines as bivalent or antigen delivery vaccines
por: Choi, Kang-Seuk
Publicado: (2017)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023)

Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2022)

Comparison of O-specific polysaccharide responses in patients following infection with Vibrio cholerae O139 versus vaccination with a bivalent (O1/O139) oral killed cholera vaccine in Bangladesh
por: Kaisar, M. Hasanul, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jgl2gfeupkc0ff5dvh18eohnll